Search results
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Morningstar· 4 days agoWINNIPEG, MB / ACCESSWIRE / April 23, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals ...
Novartis bags paediatric FDA label expansion for Lutathera
Pharmaceutical Technology via Yahoo Finance· 4 days agoTelix Pharmaceutical also expanded its radiopharmaceutical pipeline with the acquisition of QSAM...
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual...
Morningstar· 5 days agoRezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare ...
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and...
Morningstar· 3 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly...
CW39 NewsFix· 2 days agoSobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for ...
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment...
Morningstar· 6 days agoLexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced an in-license agreement with Cornell University to expedite development of the investigational ...
PANTHERx® Rare Continues Explosive Growth with Expansions of Pharmacy, HQ and Distribution Locations
FOX 8 Cleveland· 2 days agoPANTHERx® Rare, the leader in rare disease pharmacy, patient access, and support services in the...
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Zacks via Yahoo Finance· 5 days agoCorcept (CORT) reports positive data from the open-label portion of the phase III GRACE study...
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Zacks via Yahoo Finance· 5 days agoSanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III...
Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary...
WJTV Jackson· 3 days agoCBL-514 is under development for multiple indications, including Cellulite, Local Fat Reduction (currently in Phase 2b), and Durum's disease (currently in Phase 2), which brought Caliway the ...